

COVID-19 ANTIBODY THERAPY RESOURCE CENTER GUIDE

The National Infusion Center Association has developed the resources described below to support prescribers, infusion providers, and patients in the safe and efficient use of COVID-19 antibody therapeutics. These resources can be found in the [COVID-19 Antibody Therapy Resource Center](#).

Locating Sites of Care

[NICA COVID-19 Antibody Therapy Locator](#)

Currently, NICA's COVID-19 Antibody Therapy Locator is the most comprehensive database available for identifying sites of care administering COVID-19 antibody therapies.

Prescribers & Patients:

- Simply enter your city and state or your zip code and click “search”
- Click on a location to view site details including phone number, hours of operation, website, amenities, and more.
- If results do not populate for the area searched, try widening the search radius.

Note: Search results may show both “claimed” and “unclaimed” infusion sites—this only refers to whether or not the facility has signed in and updated its listing profile to customize things like hours of operation, amenities, etc. If a site is listed in our locator, it has received allocation of one or both of the COVID-19 antibody therapeutics

Infusion Providers:

- Be sure patients can find your infusion site by “claiming” your location and adding pertinent details to the profile like phone number, hours of operation, amenities, and more.
 - Consider using the URL field to direct prescribers and patients to pertinent information on your center's website, such as patient arrival instructions, required forms, etc.
 - If you need assistance claiming your center or building out your profile, email covid19@infusioncenter.org.
-

[Resources for Prescribers](#)

COVID-19 Antibody Therapy Indication Checklist

This checklist is intended to help prescribers determine if treatment with COVID-19 antibodies is authorized for use in accordance with the Emergency Use Authorization (EUA) requirements.

- If COVID-19 antibody therapy is not indicated, the checklist can be included in the medical record to document the clinical decision-making process.
- If COVID-19 antibody therapy is indicated, the checklist can accompany the medication order to document eligibility criteria and support medical necessity.†

† Individual infusion site documentation requirements may vary.

COVID-19 Antibody Therapy Order Set

An order set is developed for each approved COVID-19 antibody therapy and serves as the prescription for treatment.

- Facilitates proper prescribing by capturing the necessary elements of a valid, complete COVID-19 antibody therapy infusion order
- Captures criteria for authorized use mandatory reporting requirements per EUA.
- Includes order for substitution with alternative COVID-19 mAb if needed due to product availability (alternatively, provider may check a box to *prohibit* substitution).
- Guides infusion clinician in safe administration by prompting best practices and adherence to administration requirements.
- Supports continuity of care by prompting the infusion provider to send records of completed treatment to the prescriber.

Coding Guide

List of common diagnosis codes that may apply to eligible patients.‡

- Provides prescriber with easy access to codes needed to complete order set and indications checklist
- ICD-10 data helps public health officials understand which patient populations are receiving COVID-19 therapeutics to support efforts aimed at equitable allocation and distribution.

Referral Checklist

Many HCPs prescribing COVID-19 antibody therapeutics may be unfamiliar with the infusion referral process. As COVID-19 antibody therapeutics are thought to be most effective when given as early as possible in the disease course, it is critical to streamline the referral process to reduce unnecessary delays to expedite access to treatment and optimize outcomes. This checklist provides a template overview of necessary steps to refer a patient for COVID-19 antibody therapy.

- Infusion sites of care are encouraged to download and modify this checklist to create a custom checklist including any unique, site-specific requirements.

Patient Education: Preparing for a COVID-19 Antibody Infusion

Prescribers can provide and review this handout with patients to help them understand and prepare for their infusion to promote treatment acceptance and adherence.

- Includes a field for prescriber to indicate facility name and phone number where referral/order was sent, with instruction for patient to call if they have not received an appointment promptly. This is intended to reduce treatment delays or patients “timing out” of treatment eligibility due to communication challenges.

[Resources for Infusion Providers](#)

‡ This is not an all-inclusive list of diagnoses meeting EUA criteria for high risk for progressing to severe COVID-19 and/or hospitalization.

Casirivimab + Imdevimab Flowsheet / Bamlanivimab Flowsheet

The flowsheet, sometimes called a treatment note, is used to document all care associated with administration of COVID-19 antibody therapies.

- Guides the clinician to follow industry standards and best practices as well as adhere to administration and documentation requirements under the EUA.
- Provides a detailed record to fax to the referring prescriber for inclusion in the patient's medical record
- Especially helpful for temporary sites of care or other infusion providers using paper documentation.

Casirivimab + Imdevimab Medication Safety Alert

Casirivimab and Imdevimab are supplied in multiple packaging configurations and have unique preparation requirements that may increase risk for medication errors.

- Provides considerations and strategies to reinforce use of proper quantities/combinations of product to prepare a single dose.

Medication Preparation Area Checklist

Use this checklist to ensure the designated area where IV medications are being prepared meets national safety standards, including the National Infusion Center Association's [Minimum Standards for In-Office Infusion](#).

Medication Stability and Storage

The length of time parenteral medications may be stored following preparation varies depending on the preparation environment. This one-pager explains the reason parenteral medications prepared outside a pharmacy/"cleanroom" setting should not be stored longer than 4 hours (despite what is listed on the FDA-approved labeling).

Key Points for Preparation and Administration

This handout is a quick review of a few key pearls and pitfalls associated with preparation of monoclonal antibodies using aseptic technique. It is intended to serve as a refresher for HCPs and does not replace proper training and competency validation.

Drip Rate Tables

In sites of care administering infusions by gravity (as opposed to with an infusion pump or other rate-control device), HCPs will be required to calculate the appropriate drip rate using the volume to be infused and drop factor of the administration set used (infusion tubing). As many HCPs may be unfamiliar with the calculations required, these tables provide the appropriate drip rates for administration of both products using administration sets with any drop factor.

Patient Education: COVID-19 Antibody Therapy Discharge Instructions

This patient handout explains signs and symptoms to watch for and report following a COVID-19 antibody infusion.

- Provides home care instructions for discomfort at the IV site
- Reinforces the need to continue isolation to prevent disease transmission
- Lists emergency warning signs that necessitate seeking medical attention

[Additional Resources](#)

[NICA Standards for In-Office Infusion](#)

View NICA's minimum standards for the administration of intravenous and injectable medication in an outpatient setting.

[Eli Lilly Bamlanivimab Playbook](#)

NICA collaborated with Eli Lilly to develop this playbook with in-depth information about preparation and administration of bamlanivimab as well as other considerations for operationalizing an infusion site.

[Regeneron Casirivimab + Imdevimab Emergency Use Authorization \(EUA\) Guidebook](#)

NICA collaborated with Regeneron to develop this playbook with in-depth information about preparation and administration of casirivimab + imdevimab as well as other considerations for operationalizing an infusion site.

[Report an Adverse Event to MedWatch](#)

Healthcare providers must submit a report on all medication errors and all serious adverse events potentially related to COVID-19 antibody therapy.

[Multilingual COVID-19 Resources](#)

The CDC has developed the COVID-19 Communication Toolkit: For Migrants, Refugees, and Other Limited-English-Proficient Populations in various languages. Resources are available in Spanish, Simplified Chinese, Korean, Tagalog, Hmoob (Hmong), Af Soomaali (Somali), and Vietnamese.

